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Objective: To investigate and compare the in vitro pharmacodynamics of three carbapenems: imipenem, meropenem 
and 80-2727. 
Methods: The following studies were performed: (1) comparative studies of the rate of killing of the three carbapenems 
of reference strains of Gram-positive and Gram-negative bacteria at a concentration corresponding to the 1-h serum 
level following 500 mg intravenously in humans; (2) comparative studies of the rate of killing of 80-2727, meropenem 
and imipenem at different antibiotic concentrations of reference strains of Gram-positive and Gram-negative bacteria; 
(3) comparative studies of the rate of killing of BO-2727, meropenem and imipenem of bacteria which are phenotypically 
tolerant; (4) studies of the postantibiotic effect of BO-2727 using viable counts and optical density; (5) studies of the 
postantibiotic sub-MIC effect (PA SME) of 80-2727 using optical density. 
Results: No difference in killing rate was noted between the three carbapenems, and there was no concentration- 
dependent killing of the Gram-negative strains after 6 h. A pronounced paradoxical effect was seen against Sraphylo- 
coccus aureus. All three antibiotics were able to kill phenotypically tolerant bacteria. Only very short or no postantibiotic 
effect of 80-2727 was found against the investigated strains. Very long PA SMEs were noted for the Gram-negative 
strains, although there was a pronounced variation for the different strains of Pseudomonas aeruginosa. 
Conclusion: There was no significant difference between the studied carbapenems in their pharmacodynamic 
properties. All three antibiotics acted similarly to other p-lactam antibiotics. 
Key words: Carbapenem, imipenem, meropenem, 80-2727, pharmacodynamics, postantibiotic effect, postantibiotic 
sub-MIC effect 
INTRODUCTION 
The carbapenems, imipenem and meropenem, are 
broad-spectrum agents with excellent in vitro activity 
against Gram-positive and Gram-negative bacteria, 
including strict anaerobes. They are highly resistant to 
hydrolysis by P-lactamases, with a few exceptions such 
as the P-lactamases of Stenotrophomonas maltophilia and 
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some Aeromonas strains [1-4]. Imipenem, in contrast to 
other p-lactam antibiotics, has also been reported to 
kill non-growing bacteria [5,6] and to show a 
postantibiotic effect (PAE) not only against Gram- 
positive bacteria but also against Pseudomonas aeruginosa 
[7,8]. BO-2727 is a new carbapenem with similar in 
vitro activity to that of meropenem and imipenem. 
However, BO-2727 demonstrates even lower MIC 
values and greater in vivo activity in animal models 
against Staphylococcus aureus and l? aeruginosa in 
comparison with meropenem [9,10]. BO-2727, like 
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meropenem, is also more stable than imipenem against 
human dihydropeptidase and has a long& ha-life than 
the other carbapenems [ll]. 
To further clarify the in vitro pharmacodynamic 
properties of BO-2727 in comparison with those of 
imipenem and meropenem, the following experiments 
were performed (1) comparative studies of the rate of 
killing of the three carbapenems of reference strains 
of Gram-positive and Gram-negative bacteria at a 
concentration corresponding to the 1-h serum level 
following 500 mg intravenously in humans; (2) 
comparative studies of the rate of killing of BO-2727, 
meropenem and imipenem, at seven different 
concentrations, of reference strains of Gram-positive 
and Gram-negative bacteria; (3) comparative studies of 
the rate of m n g  of BO-2727, meropenem and 
imipenem of phenotypically tolerant bacteria; (4) 
studies of the PAE of BO-2727 using viable counts and 
optical density determinations; and (5) studes of the 
postantibiotic sub-MIC effect (PA SME) of BO-2727 
using optical density determinations. 
MATERIALS AND METHODS 
Antibiotics 
Imipenem and BO-2727 were provided by Merck, 
Sharp & Dohme, Starnberg, Germany, and meropenem 
by Zeneca, Gothenburg, Sweden. The antibiotics were 
obtained as reference powders with known potency. 
Imipenem was diluted in phosphate-buffered saline 
(PBS; pH 7.2), BO-2727 in sodium chloride (0.9%) 
and meropenem in Sorensen's buffer @H 7.0). 
Dilutions were made on the day on which the experi- 
ments were performed. 
Bacterial strains and media 
The strains used in the study were: Pseudomonas 
aeruginosa ATCC 27853 and four clinical isolates of the 
same species (strains 2060, 2057, 5003, 2049); 
Escherichia coli ATCC 25922 and four clinical isolates of 
E. coli (2084, 2089, 6023, 6024); Staphylococctrs aureus 
FDA 209P and four clinical isolates of S. aureus (3028, 
1003, 2019, 2005); and four clinical isolates of 
Acinetobacter lw08 (5030, 5063, 1092, 2035). All the 
clinical strains were obtained from the Clinical 
Microbiological Laboratory, Uppsala, Sweden. The 
Gram-negative strains were grown in Mueller-Hinton 
(MH) broth (Difco Laboratories, Detroit, MI, USA), 
supplemented with 50 mg/L of Ca2+ and 25 mg/L of 
M e ,  for 6 h at 37OC, yielding an initial inoculum of 
approximately lo9 CFU/mL for the E. coli strain, and 
5 x lo7 CFU/mL for the l? aeruginosa strain and the A.  
lwofi strain. S. aureus was grown in Todd-Hewitt broth 
(T-H), resulting in approximately lo9 CFU/mL. In the 
experiments with non-growing bacteria, PBS was used 
as nutrient-depleted medium. 
Determination of minimum inhibitory concentrations 
(MICs) 
The MICs for the strains used in experiments 1 to 3 
and in experiment 4a were determined by a macro- 
ddution technique, in MH broth (Gram-negative 
strains) or in T-H broth (S. aureus) with a final 
inoculum of approximately lo5 CFU/mL of the test 
strains, and incubation at 37 O C  for 24 h. The MIC was 
defined as the lowest concentration of antibiotic 
allowing no visible growth. 
In experiment 4b and in experiment 5, the MICs 
were determined in the BioScreen C (LabSystems, 
Helsingfors, Finland), which has been described in 
detail elsewhere [12]. Two-fold dilutions of the 
antibiotics were placed in wells in a microtiter plate 
together with the test strain with a final inoculum of 
approximately lo5 CFU/mL in liquid medmm as 
above. Growth curves were then monitored automatic- 
ally in the BioScreen C as optical density. The MICs 
were defined as the lowest concentration of the 
antibiotic that gave no increase in optical density. The 
lowest detectable level of optical density corresponded 
to 5 X lo5 CFU/mL. All MIC values are given as 
geometric means of three separate determinations. 
Experiment 1. Determination of the rate of killing 
In the first study a concentration corresponding to the 
1-h serum level following 500 mg intravenously in 
humans of the three antibiotics was used (20 mg/L for 
BO-2727, 18 mg/L for imipenem and 15 mg/L for 
meropenem). Tubes, containing adequate medium 
with the addition of the antibiotic, were inoculated 
with a suspension of the test strain, giving a final 
bacterial count of approximately 5 x lo5 CFU/mL, 
- and incubated at 37°C. Samples were withdrawn at 0, 
3, 6, 9, 12 and 24 h and, if necessary, diluted in PBS. 
Three dilutions of each sample were spread on blood 
agar plates (Colombia agar base with 5% horse blood), 
incubated at 37OC and counted after 24 h. Only plates 
with 50 to 500 colonies were counted. All three 
antibiotics were tested against S. aureus FDA 209P, E. 
coli ATCC 25922, l? aeruginosa ATCC 27853 and A.  
l w 0 8  5030; three experiments were performed for each 
antibiotic-bacterium combination. 
Experiment 2. Determination of the rate of killing at 
different concentrations 
In the second study, different concentrations of the 
three antibiotics were used. Tubes, containing 4 mL 
of either MH broth or T-H broth with antibiotic at 
2, 4, 8, 16, 32, 64 and 128 X MIC respectively, were 
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inoculated with a suspension of the test strain, giving 
a final bacterial count of approximately 5 x lo5 
CFU/mL. The tubes were incubated at 37°C and 
samples were then withdrawn and counted as described 
above. All three antibiotics were tested against S. aureus 
FDA 209P, E. coli ATCC 25922 and l? aeruginosa 
ATCC 27853; three experiments were performed for 
each antibiotic-bacterium combination. 
Experiment 3. Determination of the rate of killing of 
non-growing bacteria 
After an incubation of 6 h at 37OC in broth, 40 pL of 
the bacterial suspension was transferred to a tube with 
4 mL of PBS, giving an inoculum of approximately 
5 x l o5  CFU/mL. The tubes were then incubated at 
37OC. Three hours later, antibiotic was added at the 
same concentrations as in experiment 1 (20, 18 and 15 
mg/L respectively). One tube without antibiotic 
served as a control. The tubes were thereafter 
reincubated at 37 "C and samples were withdrawn and 
counted as described above. All three antibiotics were 
tested against S. aureus FDA 209e E. coli ATCC 25922 
and l? aeruginosa ATCC 27853; three experiments 
were performed for each antibiotic-bacterium 
combination. 
Experiment 4a. Determination of the postantibiotic effects 
using viable counts 
The PAEs of BO-2727 using viable counts were 
determined against P aeruginosa ATCC 27853 and four 
clinical strains of the same species (2060, 2057, 5003, 
2049). The PAE was also determined against S. aureus 
FDA 209 P and four clinical isolates of the same species 
(3028, 1003, 2019, 2005). AU strains were studied at 
least twice. After incubation for 6 h at 37 "C, all strains 
were diluted 1 : 10 in order to obtain an inoculum of 
approximately 5 x l o7  CFU/rnL at the beginning of 
the experiments. The strains were then exposed to 
10xMIC of BO-2727 for 2 h at 37°C. To eliminate 
the antibiotics, the strains were washed three times for 
5 min at 14008 and diluted in fresh media. The control 
strains were treated similarly. To allow monitoring 
of growth, the exposed strains were, after the 2-h 
exposure, diluted in fresh medium by a factor of 1 : 10 
or 1 : 100, or left undiluted, depending on the rate of 
lulling. In order to obtain an inoculum as close to that 
of the exposed cultures as possible, the controls were 
diluted 1 : 1000. The cultures were then reincubated at 
37°C for another 6 h. Samples were withdrawn at 0 
and 2 h (before and after dilution), and at 3, 4, 5 ,6  and 
8 h, if necessary diluted in PBS, and counted as 
described above. The PAE was defined according to the 
following formula [13]: PAE=T -C, where T is the 
time required for the viable counts of the antibiotic- 
exposed cultures to increase by one loglo above the 
counts observed immediately afier washing, and C is 
the corresponding time for the controls. 
Experiment 4b. Determination of the postantibiotic effects 
of B0-2727 in the Bioscreen G 
The postantibiotic effect of BO-2727 was investigated 
against S.  aut-eus FDA 209P, E. coli ATCC 25922, l? 
aeruginosa ATCC 27853 and A. I W O ~  5030 (two 
experiments each). Four clinical isolates of each of S. 
aureus (3028, 1003,2019,2005) and E. coli (2084, 2089, 
6023, 6024) and three isolates of each of l? aeruginosa 
(2060, 2057, 5003) and A. IwoJji (5063, 1092, 2035) 
were also studied (one experiment each). After incuba- 
tion for 6 h at 37OC, all strains were diluted 1: 10 in 
order to obtain an inoculum of approximately 5 x 10' 
CFU/mL at the beginning of the experiments. The 
strains were then exposed to 10 X MIC of BO-2727 
for 2 h at 37°C. The bacterial count had by that time 
declined by 0.5 to one loglo CFU. To eliminate the 
antibiotic, the strains were washed three times, 
centrifuged each time for 5 min at 14008 and diluted 
1 : 10 in fresh medium. The unexposed control strains 
were washed similarly but were also diluted 
in order to obtain an inoculum as close 
to that of the exposed strains as possible. Earlier 
experimental studies had revealed that the shapes of 
the growth curves of the different dilutions of the 
controls were parallel, and one loglo difference in initial 
inoculum corresponded to a constant delay in growth. 
A control curve for each strain and experiment could 
therefore be constructed with the same initial inoculum 
as the corresponding exposed strain. Since killing 
cannot be measured in BioScreen C, viable counts were 
used to measure the initial killing of the exposed 
cultures and after the washing. Viable counts of the 
controls were also performed at the start of the 
experiments, before and after washing and dilution at 
2 h. Both the exposed strains and the different dilutions 
of the controls were then diluted l : l O ,  inoculated in 
microtiter wells of 400 pL and incubated in the 
Bioscreen C. Growth curves were measured automatic- 
ally as optical density in the computer every 10 min for 
20 h. The PAE was calculated as the difference in time 
for the exposed cultures and the corresponding control 
to grow up to a defined point (A~o)  n the absorbance 
curve, where A50 was defined as 50% of the maximal 
absorbance of the control. A 5 0  was chosen, since this 
point represented approximately growth of one loglo 
CFU [12,14]. 
and 
Experiment 5. Determination of the postantibiotic sub-MIC 
effects (PA SME) of B0-2727 
The PA SMEs of BO-2727 were determined for the 
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reference strains on two merent occasions and once 
for the clinical strains. The postantibiotic phase was 
induced as described above and the control curves were 
diluted the same way as in the PAE experiments. Viable 
counts were also used as described above. The strains 
in the postantibiotic phase and the Merent dilutions of 
the controls were then exposed to 0.1, 0.2, 0.3, 0.4 
and 0.5 x MIC of BO-2727 and incubated in the 
BioScreen C. Growth curves were monitored auto- 
matically for 20 h. The PA Sh4E was defined as the 
Merence in time taken between the exposed cultures, 
later exposed to sub-MICs, and the corresponding 
controls with the same initial inoculum as the pre- 
exposed culture, to reach A50 (defined as above) 
[ 12,143. 
RESULTS 
Minimum inhibitory concentrations 
The MIC values for BO-2727, imipenem and 
meropenem against the strains studied are shown in 
Table 1. BO-2727 and imipenem had two- to three- 
fold lower MIC values against S. aureus compared to 
meropenem measured by visibdity. Imipenem showed 
Table 1 Minimum inhibitory concentrations of the 
carbapenems 
~~ ~ ~~ ~ ~~ 
BO-2727 
optical 
Strains Visibility density Imipenem Meropenem 
S. aurcuc 
209P 0.06 0.13 0.03 0.25 
3028 0.03 0.03 
1003 0.06 0.06 
2019 0.06 0.06 
2005 0.06 0.06 
E.  coli 
ATCC 25922 0.13 0.06 0.25 0.03 
2084 ND 0.06 
2089 ND 0.13 
6023 ND 0.13 
6024 ND 0.13 
I! aeruginosa 
ATCC 27853 1.0 0.5 4.0 0.5 
2060 0.5 0.5 
2057 0.5 0.5 
5003 0.5 0.25 
2049 1 .o 2.0 
A. lw$ 
1-5030 0.13 0.06 0.06 1.0 
5063 ND 0.13 
1092 ND 0.03 
2035 ND 0.25 
ND=noc done. 
the highest MIC value against l? aeruginosa. BO-2727 
showed overall low MIC values against the studied 
strains. The difference in MIC values between the two 
methods (viable counts and BioScreen C) was not more 
than one dilution step. 
Experiment 1. Rate of killing at a concentration reached in 
human serum 1 h after 500 mg intravenously 
No Merences in killing rate between the three 
antibiotics were seen against S. aureus 209P (Figure l), 
l? aeruginosa ATCC 27853 and E. coli ATCC 25922. 
However, a three loglo better kdhg was noted after 
3 h for BO-2727 and imipenem against A. lwoj55030 
in comparison with meropenem. This Merence was 
no longer apparent after 12 h. 
Experiment 2 Rate of killing at different concentrations 
Maximal killing was already reached at 4 to 8 x MIC 
with all three carbapenems against l? aeruginosa, and no 
further concentration-dependent killing was found 
thereafter. Against E. coli, all the carbapenems showed 
a concentration-dependent killing up to 6 h. There- 
after, there was no difference between the killing 
reached with 8 XMIC and that with the higher 
concentrations. Figure 2 shows the killing effect ofBO- 
2727 on E. coli ATCC 25922. A notable paradoxical 
effect was found for all carbapenems against S. aureus, 
where 4 x M I C  gave on average a three loglo better 
killing in CFUs than 128 x MIC. 
Experiment 3. Rate of killing of non-growing bacteria 
All three carbapenems were able to kill non-growing 
bacteria. Imipenem induced a five log10 decrease in 
CFU of E. coli ATCC 25922 after 12 h compared to a 
three loglo decrease for meropenem and a 2.5 loglo 
decrease for BO-2727 (Figure 3). Against I? aeruginosa 
ATCC 27853 both imipenem and BO-2727 induced a 
two loglo decrease in CFUs compared to a one loglo 
decrease for meropenem. Imipenem was the only anti- 
biotic that was able to kill non-growing S. aureus 209P 
Experiments 4a. 4b and 5. Postantibiotic effects and 
postantibiotic sub-MIC effects of B0-2727 
No or only very short PAEs (less than 1 h) were found 
for all strains investigated (l? aeruginosa 2057, 2049; 
S. aureus FDA 209 P, 1003, 2019, 2005) with viable 
counts. In the BioScreen C, a short PAE was noted for 
all strains of S. aureus except for s t r a i n  3028. No PAE 
could be demonstrated against the Gram-negative 
strains except for one clinical strain of E. coli (2084) and 
one ofA. lwoffi (2035), 0.9 h and 3.1 h respectively. AU 
st ra ins  of A.  lwofi and E. coli were extremely sensitive 
to sub-MICs in the postantibiotic phase with a delay in 
regrowth up to more than 20 h at 0.4 X MIC. The PA 
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experiments. 
Killing curves of BO-2727 at different concentrations against Eschen'chia coli ATCC 25922. Mean of three 
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of three experiments. 
Killing curves of imipenem, meropenem and BO-2727 against non-growing Escherichia coli ATCC 25922. Mean 
SMEs of I? aeruginosa and S. aureus were usually shorter 
and varied among the strains investigated (Table 2). , 
DISCUSSION 
Several pharmacodynamic parameters, such as the rate 
of bacterial m n g ,  whether the killing rate is 
concentration-dependent or not and postantibiotic 
effects have been recognized as important factors that 
may influence the optimal dosing regimens for 
antibiotics [13,15-171. In the present study, we have 
compared these pharmacodynamic parameters for 
imipenem, the first carbapenem to be introduced on 
the market, meropenem and BO-2727, a new 
carbapenem which, like meropenem, is stable to renal 
dehydropeptidase. In this study, no significant differ- 
ence was found between the three carbapenems in their 
killing rate, except that BO-2727 showed a better 
initial killing of A.  Iwo@. All three carbapenems 
exhibited rapid killing of the Gram-negative strains, 
with a decrease of approximately four loglo CFUs 
during the first 6 h. A maximal killing was reached 
already at 4-8xMIC with all three carbapenems 
against l? aeruginosa, and no further concentration- 
dependent killing was found thereafter. An initial 
concentration-dependent killing up to 6 h was, 
however, seen against E .  coli. For S. aureus, the killing 
was much slower, with a decrease of only approximately 
0.5 loglo CFUs after 24 h, and a notable paradoxical 
effect was also found for all three carbapenems against 
this species. Ths so-called Eagle effect was described 
early in the literature but the clinical implications of this 
effect are not clear [18-21]. The lack of faster killing 
in spite of higher concentrations of the carbapenems 
in our study is in agreement with studies on other 
p-lactam antibiotics [22,23]. 
A phenomenon discovered early in the antibiotic 
era was that penicfin did not exert a bactericidal effect 
on non-growing bacteria [24]. This characteristic was 
later shown to be common to most p-lactam anti- 
biotics, with the exception of imipenem, which was 
shown to be able to lull non-growing bacteria [5,6]. In 
our study we could show that all three carbapenems 
were able to kill non-growing Gram-negative bacteria, 
but imipenem was the only agent able to kill non- 
growing S. aureus 209 P. 
A pharmacodynamic factor that has attracted great 
interest during the last 10 years is the postantibiotic 
effect (PAE), i.e. the inhibition ofbacterial growth after 
short exposure to antibiotics [7,13,25-271. In general, 
p-lactam antibiotics do not exert any PAE against 
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Table 2 The postantibiotic effect (PAE) and the 
postantibiotic sub-MIC effect (PA SME) of BO-2727 
(h) PA SME (h) 
( x MIC) 
VC OP 0.1 0.2 0.3 0.4 0.5 
S. aureus 
209P 0.1 
3028 0 
1003 0 
2019 0.3 
2005 0 
I! aeruginosa 
ATCC 27853 -0.3 
2060 -0.9 
2057 0.5 
2049 0.4 
5003 -0.7 
E. coli 
ATCC 25922 ND 
2084 ND 
2089 ND 
6023 ND 
6024 ND 
A .  lwofi 
5030 ND 
5063 ND 
1092 ND 
2035 ND 
0.9 
0 
0.8 
0.9 
0.5 
0.2 
-3.0 
-0.6 
-3.0 
ND 
-0.3 
0.9 
0 
0 
0.2 
-0.3 
0 
0 
3.1 
0.9 4.3 >20 >20 >20 
1.0 1.9 4.0 6.9 >20 
0.9 1.8 3.2 5.2 8.8 
0.6 1.2 1.9 3.9 7.0 
0.7 1.5 3.2 5.7 11.1 
0.6 3.3 8.9 10.6 13.4 
2.4 10 12.6 >20 >20 
ND ND ND ND ND 
-2.6 1.4 4.8 6.6 6.3 
-2.7 -2.1 -0.9 4.9 7.0 
0 8.9 17.7 >20 >20 
2.7 5.2 9.0 >20 >20 
1.4 3.3 9.0 >20 >20 
0.1 >20 >20 >20 >20 
10 >20 >20 >20 >20 
VC=viable counts; OP=optical density (mean values); ND=Not 
done. 
Gram-negative bacteria, with the exception of carba- 
penems, which may produce a PAE on some Gram- 
negative organisms such as l? aeruginosa, depending on 
the method used [8, 28-30]. In this study, the PAE of 
BO-2727 was investigated with two different methods, 
viable counts and optical density. As shown earlier, 
there were only minor differences between the two 
methods [12,14]. No or a negative PAE could be 
demonstrated against the Gram-negative strains except 
for one clinical strain of E. coli (2084) and one of A.  
lwo8 (2035), 0.9 h and 3.1 h respectively. The negative 
PAE seen in the study is explained by the formation of 
filamentous bacteria during the exposure to BO-2727. 
At the time of drug removal and during the 
postantibiotic phase, cell division occurs, yielding a 
more rapid increase in the number of bacterial cells 
than in the control cultures. Only with lower inoculum 
at the induction of the PAE (inoculum of lo3 
C F U / d )  could a PAE of over 1 h be seen against P 
aetuginosa with viable counts (data not shown). This is 
in agreement with earlier studies on imipenem and 
meropenem [8,11]. A short PAE against most of the S. 
aureus strains was noted in the BioScreen. 
When PAE is determined, the bacteria are exposed 
to the antibiotic for a limited period of time at a given 
constant concentration, followed by removal of the 
antibiotic. This is in contrast to the clinical situation, 
where bacteria will be exposed to suprainhibitory 
concentrations followed by subinhibitory levels (sub- 
MICs). We have previously studied the influence of the 
effect of sub-MICs on bacteria in the postantibiotic 
phase, and found a very long delay in bacterial regrowth 
for many antibiotic classes and different bacterial species 
(postantibiotic sub-MIC effect; PA SME) [31-351. In 
the present study, we showed that all strains of A.  lwofi 
and E. coli were extremely sensitive to sub-MICs of 
BO-2727 in the postantibiotic phase, with a delay in 
regrowth up to more than 20 h at 0.4 x MIC. The PA 
SMEs for l? aeruginosa and S. aureus varied among the 
strains but were, in general, shorter. The values of PA 
SME for l? aeruginosa corresponded well with those 
found with meropenem in an earlier study [14]. 
Studies of the pharmacodynamics of antibiotics in 
vitro, in animal models and in humans have shown that 
the optimal dosing regimen varies with different 
antibiotics, different bacterial species and the status of 
the host defense [36-411. Experimental studies in 
immunocompromised animals and clinical studies in 
immunocompromised patients have shown that the 
time for which fiee serum levels exceed the MIC is the 
major determinant of efficacy of p-lactam antibiotics 
[36-381. In the present study, no Merence between 
the three carbapenems in the studied pharmaco- 
dynamic parameters was noted. This class of antibiotics 
seems to show variable concentration-dependent 
U n g  depending on the bacterial species studied, a 
paradoxical effect against S. aureus, a short PAE or no 
PAE at all, and a variable PA SME. Therefore, it seems 
that the most important parameter predicting efficacy 
in vitro is the time above the MIC. This has also been 
shown in vivo for imipenem in an animal model 
[36,38] but clinical trials with Merent dosing regimens 
must be performed to confirm the hypothesis. 
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